Alkem Laboratories Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/2qlm8pavbuop2ktcir4eqiep.pdf

Key Takeaways


Margin Performance & Sustainability

Sandeep Singh: "I think forget the quarter; quarter is great but this is not sustainable on an annual basis. I think we will be close to 16.5 for this year, year ending."

US Business: Pricing, Mix & Pipeline

Dr Vikas Gupta: "So, just to add to it, Nithya, the mix that we have in US, we are not sure whether the same mix will continue in the coming quarters as well. So, that you may still, if you want to qualify as a one-off, you may look at that."

Domestic Business: Chronic Strength, Acute Weakness

Dr Vikas Gupta: "So, chronic, we have a clear strategy that we have in place and that's one of the most important areas and levers of growth for domestic business in India."

Enzene Bioscience: Early-Stage Investment Thesis

Sandeep Singh: "I think this is very early stage for biotech. So, honestly for the next 3-4 years, we really should not expect it to like to generate a lot of profit even though even if they breakeven but I think growth is a priority here."

R&D, Filings & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
EBITDA margin~16.5% for full year FY24; Q2's 17.5% not sustainable annuallyFY24
Gross margin59%–59.5% on annualized basis; confident of matching 59.5%FY24
US dollar revenue growthHigh single-digit growth in dollar termsFY24 over FY23
ANDA filings8–9 filings, back-ended in H2FY24
Tax rateRevised to 12%–15% from ~18%FY24
Sikkim tax benefitBenefit lasts until March 2026; no fixed benefit from April 2026 onwardThrough Mar 2026
Denosumab US commercializationLate 2026 targetLate 2026
Enzene Bioscience profitabilityDo not expect significant profit; growth is the priorityNext 3–4 years

Key Metrics

MetricQ2 FY24
Revenue from operationsNot explicitly stated for Q2 FY24 in transcript or scratchpad
EBITDA margin21.7%
Net profit after tax₹620 cr
Cash generated from operations₹470 cr during the quarter
Net cash position₹2,900 cr as of September 30, 2023
Gross margin~61% (per an analyst's math)
International business revenueSurpassed ₹1,000 cr for the second consecutive quarter
US pricing deflation~5% to 6% (big single digit)
ANDA approvals4 approvals including 1 tentative approval during the quarter
India field force~12,000 first-line MRs
Trade generic business contribution~20% to 21% of domestic business, growth of 6% to 7%
Enzene Bioscience cost₹80 cr in Q2 FY24, profitability slightly negative but close to breakeven
Tax rate guidanceRevised to 12% to 15% for FY24 from earlier ~18%
Full year FY24 EBITDA margin guidance~16.5%
Full year FY24 gross margin guidanceMaintained at 59% to 59.5% on an annualized basis